Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment
Maojun Zhou, Hao Zheng, Yubin Li, Huichao Huang, Xiaoli Min, Shuyan Dai, Wenqiang Zhou, Zhuchu Chen, Guangyu Xu, Yongheng Chen
Abstract
and in a CRPC xenograft model. These results provide preclinical proof of principle for Zeta55 as a promising therapeutic in prostate cancer treatment.
Topics & Concepts
Prostate cancerHDAC6Androgen receptorCancer researchProstateCancerTMPRSS2AcetylationMedicineHistone deacetylaseChemistryPharmacologyInternal medicineHistoneDiseaseBiochemistryCoronavirus disease 2019 (COVID-19)GeneInfectious disease (medical specialty)Histone Deacetylase Inhibitors ResearchProstate Cancer Treatment and ResearchPeptidase Inhibition and Analysis